Search PubMed⌕ Search

Biomedical subjects

H Huland

Publications and source records attributed to H Huland.

At least 217 records · Page 12Linked to original sources
PubMed1987

Monoclonal antibody 486 P 3/12: a valuable bladder carcinoma marker for immunocytology.

Monoclonal antibodies directed against tumor-associated antigens of bladder carcinoma were used to identify tumor cells in bladder washout specimens of 40 patients with bladder carcinoma (group 1), 41 with no bladder disease or with urinary tract infections (group 2), 41 who received long-term mitomycin C instillation therapy after excision of the tumors (group 3) and 39 who received no prophylaxis after excision of the tumors (group 4). In all groups the same bladder washout specimen was used for standard urinary cytological and immunocytological tests. True positive results were obtained in 90 per cent of the patients in group 1 according to our immunocytological criteria and in 43 per cent according to standard cytology studies. No urine specimens in group 2 (controls) were immunocytologically positive, while 16 of 41 in group 3 and 17 of 39 in group 4 were positive immunocytologically but only 4 and 5, respectively, were positive according to standard cytology studies. Further followup of these patients will show whether cells positive for monoclonal antibody 486 P 3/12 will permit early detection of recurrent bladder cancer and whether one can identify patients who require prophylaxis after removal of the superficial bladder tumors.

Antibodies, Monoclonal↗
PubMed1987

Monoclonal antibodies for characterization of the heterogeneity of normal and malignant transitional cells.

We present two monoclonal antibodies (mab), Mano 4/4 and 486 P3/12, directed against tumor-associated antigens of different subpopulations of transitional cell bladder carcinoma tumors. A detailed description is given concerning their reactivity patterns in an ELISA assay against different cell lines. Using immunohistochemical staining against normal bladder mucosa, mab Mano 4/4 reacts with distinct cells in the basal layer and mab 486 P 3/12 recognizes single cells in the superficial layer. Analysing different transitional-cell carcinomas, mab Mano 4/4 reacts with 17 of 20 and mab 486 P 3/12 with 17 of 19 bladder tumors. It is emphasized that both mabs may add new information in respect to a better characterization of the heterogeneity of bladder carcinoma. A biochemical characterization of the mabs and their corresponding antigens is given. Mab Mano 4/4 is directed against a 28 kD glycoprotein and mab 486 P 3/12 is reacting with a 200 kD glycoprotein belonging to the family of CEA-like proteins.

Antibodies, Monoclonal↗
PubMed1987

Xenogenic transplantation of human bladder- and renal-cell carcinoma into NMRI mice treated with cyclosporin A and into NMRI nu/nu mice. Introduction of a new experimental cancer model.

128 tumors from three different human renal-cell carcinomas and from one human transitional bladder cancer were transplanted into NMRI mice treated with cyclosporin A at various dosages. Their acceptance rate, proliferation rate, and morphologic and growth characteristics were studied and compared with those of the same human tumors after transplantation into NMRI nu/nu mice. The acceptance rate was 80% in mice treated with cyclosporin A at 100 mg/kg-1 and 150 mg/kg-1/day. The highest acceptance rate was observed after transplantation into nu/nu (thymus-aplastic) mice (100%). Morphologically, the transplanted tumor was similar in the two animal groups and identical with the primary tumors. Metastases were not seen in either animal model. The NMRI mice treated with cyclosporin A had leukocyte infiltration into the transplanted tumor. The growth rate of the human tumors in normal mice depended on the cyclosporin A dosage, and was highest in the nu/nu mice. The proliferation rates of the transplanted human tumors, as judged by flow cytometry, were rather similar in all groups.

Animals↗
PubMed1987

Long-term serial transplantation of different human bladder carcinomas into NMRI nu/nu mice. Histologic, flow cytometric and growth studies.

Sixteen human bladder carcinomas (BCs) were transplanted into NMRI nu/nu mice with an acceptance rate of 62.5%. Six of the 16 (37.5%) BCs were successfully retransplanted up to 14 passages. Histologic grading and traumatization during surgery influenced the acceptance rate. Grade-I tumors were rarely accepted, unless they were obtained during open surgery, rather than by transurethral resection (TUR). Specimens taken by TUR or by electric cut during open surgery were almost never accepted. Identity of the transplanted tumor tissue with the original human BCs could be demonstrated by flow cytometry and by light microscopy through several passages in all accepted tumors. However, although the tumors retained their major structural features, their proliferative activity increased, particularly that of grade-I tumors. The five tumors that were transitional-cell carcinomas and could be subpassed had three characteristics not seen before in transplanted renal cell carcinomas: tumor growth started after a delay which shortened with each further passage; growth rates of tumors only in their first passage correlated with the prognosis of the corresponding patients, and with each further passage, tumor growth accelerated until a doubling time of about 1 week was observed. From then on, tumor growth was almost identical in all five tumors. In contrast to our experience with transplanted renal cell carcinomas, flow cytometric evaluation of the transplanted and further passaged BCs revealed changes in DNA index and an increase in proliferative rate and it seems that BCs were strongly influenced by host factors.

Animals↗
PubMed1986

[Pyelonephritic scar formation].

Pyelonephritic scars almost never develop after urinary tract infections alone, but require in addition certain risk factors. The most important risk factors are: vesicoureteral reflux, intrarenal reflux, obstructive uropathy, and nephrolithiasis. Most of the pyelonephritic scars develop in early childhood, where we find the combination of vesicoureteral reflux, intrarenal reflux, and urinary tract infections. Urinary tract infections alone almost never result in pyelonephritic scars. After the age of 3 years the risk to develop pyelonephritic scars is not more than 10% in those with the combination of urinary tract infections and vesicoureteral reflux. In this age group the risk to develop pyelonephritic scars is not altered by antireflux operation.

Adult↗
PubMed1986

Influence of thromboxane A2 inhibition on the development of hydronephrotic atrophy.

The development of hydronephrotic atrophy as measured by dry and wet weight in relation to wholebody weight, in rats after complete unilateral ureteral obstruction could be influenced by oral administration of OKY 1581, an inhibitor of thromboxane A2 synthesis. The data are consistent with the thesis that preglomerular thromboxane A2-mediated active vasoconstriction is involved, most likely by ischemia, in the development of hydronephrotic atrophy, at least in the renal cortex.

Animals↗
PubMed1986

Human transitional cell carcinoma in the NMRI-nu/nu mouse bladder: a new animal model for the in vivo use of monoclonal antibodies and cytotoxic agents.

Human transitional cell carcinoma of the bladder was successfully transplanted into the bladder of the NMRI-nu/nu mouse. Transplantation of a single-cell suspension from a human Grade II transitional cell carcinoma had an acceptance rate of 33%. The tumors showed invasive growth and could be identified by an anti-human monoclonal antibody. This tumor model can be valuable as an in vivo test system for the local use of cytotoxic agents and monoclonal antibodies in diagnosis of and therapy for human bladder carcinoma.

Animals↗
PubMed1985

Noninvasive ultrasound in detecting and staging bladder carcinoma.

Patients with suspected bladder abnormalities were examined by noninvasive suprapubic sonography to define the accuracy of ultrasound for detecting and staging bladder carcinomas. In 103 patients, 65 tumors were found by cystoscopy, of which sonography detected 61 (94%). Four lesions less than 2-3 mm were missed at the bladder dome, the ventral wall, and side wall. The sonographic staging was correct in 83% of all tumor stages with the lowest value of 69% for T2/T3a tumors; excluding recurrent tumors, the overall accuracy increased. From these results, suprapubic sonography is considered to be a reliable noninvasive technique for detecting bladder tumors and for preoperative local staging. The staging results are comparable with reports in the literature on the accuracy of intravesical sonography.

Aged↗
PubMed1985

Transplantation of human renal cell carcinoma into NMRI nu/nu mice. III. Effect of irradiation on tumor acceptance and tumor growth.

Irradiation of human renal cell carcinoma before radical tumor nephrectomy resulted in a significantly lower acceptance rate (1 of 7) in nude mice than for nonirradiated tumors (all of 13). The tumor tissue was transplanted into NMRI nu/nu mice immediately after nephrectomy. In this experimental system we demonstrated the reduced vitality of human tumor cells after irradiation. In a second series of experiments, 3 morphologically different human renal cell carcinomas were irradiated at various doses after establishment in nude mice. The irradiated tumor tissue was transplanted to the next passage. The morphology, proliferation rate and growth of these tumors were compared with those of nonirradiated controls. Radiation effect was dose dependent in the responding tumor types. The characteristics correlated with radiosensitivity were high proliferation rate (measured by flow cytometry), low cytologic grading and fast growth rate in the nude mice.

Animals↗
PubMed1985

Chemotherapy and human bladder carcinoma transplanted into NMRI nu/nu mice.

Transitional and squamous-cell carcinomas of the bladder that were transplanted and successfully retransplanted in further passages to NMRI nu/nu mice were used to test the efficacy of chemotherapy. Mitomycin and bleomycin consistently retarded tumor growth; results with platinex and methotrexate were variable. Combination therapy was not much better than single-drug therapy. Substances that proved effective in the mouse model produced some response in the corresponding patients in a series of patients on specific chemotherapy. In a previous study we have shown that tumor growth of transplanted human bladder carcinoma accelerates, unlike transplanted renal cell carcinoma when successfully subpassaged, resulting in a uniformly fast growing rate similar in all transplanted tumors including those which initially started with slow growing rates. Most importantly, however, tests in a given tumor conducted on a slow-growing early passage and on a fast-growing late passage produced different results. We concluded that this finding might explain the clinical observation that tumor remission due to chemotherapy in patients with metastatic bladder carcinoma does not last very long and seldom prolongs survival. It is assumed--it is not proved--that substances that proved effective in fast growing passages are probably likely to yield greater prolongation of life than those effective in slow-growing passages.

Aged↗
PubMed1985

Association of N-acetyltransferase polymorphism and environmental factors with bladder carcinogenesis. Study in a north German population.

The N-acetyltransferase phenotype was determined in 105 German patients with bladder carcinoma and in a control group of 42 healthy subjects. The slow phenotype was significantly more frequent among the patients (61.9% compared to 42.9% in the control group). Potential risk factors like occupational exposure, smoking habits, drug abuse and urological anamnestic predispositions were evaluated in relation to staging and grading of the disease, and acetylator phenotype.

Acetyltransferases↗
PubMed1985

A modified Pak test to diagnose hypercalciuria in outpatients.

A modification of the so-called Pak test to classify hypercalciuria in outpatients was evaluated. With the original Pak test, 25-31% of our patients with proven hypercalciuria and stone disease could not be classified mainly because of the low-calcium diet used in preparation for the test. By using sodium cellulose phosphate 4 days before the Pak test instead of a low-calcium diet we reduced the incidence of unclear results from 31 to 3% in the same patients.

Ambulatory Care↗
PubMed1985

Use of mitomycin as prophylaxis following endoscopic resection of superficial bladder cancer.

A prospective controlled study evaluated the influence of long-term mitomycin instillation therapy on tumor recurrence, tumor progression rate, and patient survival after transurethral resection of superficial bladder tumors. In the mitomycin group, 11.1 per cent had recurrent tumors, and among the controls, 54.8 per cent had recurrent tumors during a mean follow-up of thirty-three and one-half and thirty-four and one-half months, respectively. The control group had 8 recurrent tumors of higher stage and 4 of higher grade, whereas all recurrent tumors in the mitomycin group that occurred in the bladder were either the same grade and the same stage (n = 1) or a lower stage and lower grade (n = 6). Side effects were minimal, with 72 per cent of the patients having no side effects. Chemical cystitis was the most common side effect, followed by generalized rash. No general toxic signs such as myelosuppression were seen.

Administration, Topical↗
PubMed1984

[The pelvis and urinary organs from the surgical and urologic viewpoint].

Our joint urological and surgical statements demonstrate that in cases of injuries of the pelvic ring and urinary organs there are numerous measures which guarantee adequate primary treatment. They also make it possible to postpone final and definitive treatment. On the other hand predictable as well as unpredictable complication may prevent timely reconstructive operations and may thus impair the final outcome. The purpose of this paper is to emphasize the importance of the fact that the treatment of a polytraumatized patient should be planned by the surgeon who is most experienced in traumatology.

Female↗